Skip to main content

brelovitug

·Code: BJT-778

brelovitug: sourced relationships with 1 company · 4 clinical trials tracked.

brelovitug evidence translation

What we can confirm

What it means

Source-backed records connect brelovitug to MIRM; that link alone does not prove the drug works.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

How could brelovitug → MIRM affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence2 indications · 0 study sponsors

Related indications

Chronic Hepatitis D Infection; Chronic Hepatitis DChronic Hepatitis D Infection

Study sponsors

No additional listed-company sponsor is linked.

Dated Pipeline Records (1)
CompanyDated record stage
Mirum Pharmaceuticals, Inc. (MIRM)
developer · Reported 2026-02-25 · Current development: unknownSource
Chronic Hepatitis D Infection; Chronic Hepatitis D
Phase 3
Clinical Trial Registry Records (4)

A Phase 2b/3, Open-Label, Multicenter Trial Evaluating the Efficacy and Safety of Switching to Brelovitug for the Treatment of Chronic Hepatitis Delta Infection in Participants Receiving Bulevirtide (AZURE-3)

NCT07454837Registry updated 2026-09-10·Phase 2/Phase 3·MIRM
Recruiting

Primary endpoint: Proportion of participants with undetectable HDV RNA (<LLOQ Target not detected [TND])

InterventionalRandomizedopen120 targetStarted 2026-02Completion 2029-0344 sites · Austria, Czechia, France, Germany…Mirum Pharmaceuticals, Inc.

A Randomized, Open-label, Multicenter, Phase 3 Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4)

NCT07298330Registry updated 2026-06-29·Phase 3·MIRM
Active, not recruiting

Primary endpoint: Percentage of participants with a composite endpoint of virologic response and ALT normalization at Week 24 in brelovitug arms compared to response at Week 12 of delayed-treatment arm

InterventionalRandomizedopen80 targetStarted 2026-01Completion 2029-0127 sites · Belgium, Bulgaria, Georgia, Hungary…Mirum Pharmaceuticals, Inc.

A Global, Randomized, Open-label, Multicenter Phase 3 Trial Evaluating BJT-778 vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)

NCT07200908Registry updated 2026-10-08·Phase 3·MIRM
Recruiting

Primary endpoint: Percentage of participants with a composite endpoint of virologic response and ALT normalization

InterventionalRandomizedopen172 targetStarted 2025-08Completion 2029-0957 sites · Austria, Czechia, France, Germany…Mirum Pharmaceuticals, Inc.

A Global, Randomized, Open-label, Multicenter, Phase 2b/3 Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-1)

NCT06907290Registry updated 2026-03-02·Phase 2/Phase 3·MIRM
Active, not recruiting

Primary endpoint: Percentage of participants with a composite endpoint

InterventionalRandomizedopen150 targetStarted 2025-03Completion 2029-0938 sites · Australia, Bulgaria, Canada, Georgia…Mirum Pharmaceuticals, Inc.

Frequently asked questions

Which companies have sourced relationships with brelovitug?

brelovitug has dated SEC/FDA relationship records for Mirum Pharmaceuticals, Inc..

How many clinical trials involve brelovitug?

BioSniper tracks 4 clinical trials involving brelovitug.